Novartis AG
NVS Real Time Price USD$NVS is featured in our Shelley Moore Capito and Tom Carper strategies.
All StrategiesRecent trades of NVS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVS holdings by institutional investors
Quarterly net insider trading by NVS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
NVS Estimated quarterly lobbying spending
NVS Revenue by Segment or Geography
New NVS patent grants
-
Patent Title: Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain Feb. 27, 2024
-
Patent Title: Mammalian expression vector Dec. 27, 2022
-
Patent Title: Container for pharmaceuticals Aug. 02, 2022
-
Patent Title: Container for pharmaceuticals Aug. 02, 2022
-
Patent Title: Glycoside derivatives and uses thereof May. 24, 2022
-
Patent Title: Cell culture medium Dec. 28, 2021
-
Patent Title: Display screen with graphical user interface Nov. 23, 2021
-
Patent Title: Injection device Aug. 24, 2021
-
Patent Title: Injection device Aug. 24, 2021
-
Patent Title: Injection device Aug. 24, 2021
-
Patent Title: Injection device Aug. 24, 2021
-
Patent Title: Display screen with graphical user interface Jun. 15, 2021
-
Patent Title: Display screen with graphical user interface Jun. 15, 2021
-
Patent Title: Display screen with graphical user interface Jun. 15, 2021
-
Patent Title: Packaging box Feb. 16, 2021
-
Patent Title: Packaging box Feb. 09, 2021
-
Patent Title: Methods of treating cancer with low density lipoprotein-related protein 6 (lrp6)—half life extender constructs Feb. 18, 2020
-
Patent Title: Contact lens Dec. 10, 2019
-
Patent Title: Injector and insert for an injector Mar. 19, 2019
-
Patent Title: Intraocular lens delivery device Feb. 19, 2019
-
Patent Title: Auto-injector Jan. 29, 2019
-
Patent Title: Auto-injector Jan. 29, 2019
-
Patent Title: Auto-injector Jan. 29, 2019
-
Patent Title: Auto-injector Jan. 29, 2019
-
Patent Title: Auto-injector Jan. 29, 2019
-
Patent Title: Auto-injector Jan. 29, 2019
-
Patent Title: Container for pharmaceuticals Nov. 06, 2018
-
Patent Title: Contact lens Oct. 02, 2018
-
Patent Title: Contact lens Sep. 25, 2018
-
Patent Title: Contact lens Sep. 25, 2018
-
Patent Title: Contact lens Sep. 25, 2018
-
Patent Title: Contact lens Aug. 07, 2018
-
Patent Title: Contact lens Jul. 31, 2018
-
Patent Title: Contact lens Jul. 31, 2018
-
Patent Title: 4-piperidinyl compounds for use as tankyrase inhibitors Jul. 10, 2018
-
Patent Title: Methods for producing vaccine adjuvants Jun. 26, 2018
-
Patent Title: Packaging box Jun. 19, 2018
-
Patent Title: Pyridine and pyrazine derivative for the treatment of cf Mar. 20, 2018
-
Patent Title: Circulation of components during homogenization of emulsions Jun. 20, 2017
-
Patent Title: Pupil expander May. 17, 2016
-
Patent Title: Pupil expander May. 17, 2016
-
Patent Title: Extended depth of focus (edof) lens to increase pseudo-accommodation by utilizing pupil dynamics Apr. 12, 2016
-
Patent Title: Dosing card for a topical preparation Feb. 02, 2016
-
Patent Title: Container for storage Dec. 08, 2015
-
Patent Title: Inhibitors of cyp 17 Sep. 30, 2014
-
Patent Title: Vaccines for protecting against influenza Sep. 03, 2013
-
Patent Title: Vaccines for protecting against influenza Sep. 03, 2013
-
Patent Title: Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use Jan. 15, 2013
-
Patent Title: Powder filling apparatus and methods for their use Nov. 22, 2011
-
Patent Title: Pharmaceutical compositions Dec. 28, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVS from public contracts
Recent insights relating to NVS
Recent picks made for NVS stock on CNBC
ETFs with the largest estimated holdings in NVS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVS stock a Buy, Sell, or Hold?
- What is the price target for $NVS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVS stock?
- Who owns the most shares of $NVS stock?
- What funds own $NVS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.